AUPH vs. BMY
Compare and contrast key facts about Aurinia Pharmaceuticals Inc. (AUPH) and Bristol-Myers Squibb Company (BMY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: AUPH or BMY.
Correlation
The correlation between AUPH and BMY is 0.40, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
AUPH vs. BMY - Performance Comparison
Key characteristics
AUPH:
1.30
BMY:
0.42
AUPH:
2.13
BMY:
0.83
AUPH:
1.24
BMY:
1.10
AUPH:
0.67
BMY:
0.25
AUPH:
4.00
BMY:
1.54
AUPH:
14.28%
BMY:
7.80%
AUPH:
44.59%
BMY:
30.47%
AUPH:
-87.58%
BMY:
-70.62%
AUPH:
-75.48%
BMY:
-35.75%
Fundamentals
AUPH:
$1.13B
BMY:
$101.88B
AUPH:
$0.04
BMY:
$2.68
AUPH:
206.50
BMY:
18.68
AUPH:
0.00
BMY:
2.26
AUPH:
4.77
BMY:
2.14
AUPH:
2.97
BMY:
5.92
AUPH:
$184.83M
BMY:
$47.64B
AUPH:
$164.33M
BMY:
$31.43B
AUPH:
$32.49M
BMY:
$16.18B
Returns By Period
In the year-to-date period, AUPH achieves a -9.69% return, which is significantly higher than BMY's -15.29% return. Over the past 10 years, AUPH has outperformed BMY with an annualized return of 7.84%, while BMY has yielded a comparatively lower -0.53% annualized return.
AUPH
-9.69%
12.64%
-2.76%
57.48%
-14.21%
7.84%
BMY
-15.29%
-11.66%
-12.43%
12.63%
-1.61%
-0.53%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
AUPH vs. BMY — Risk-Adjusted Performance Rank
AUPH
BMY
AUPH vs. BMY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Aurinia Pharmaceuticals Inc. (AUPH) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
AUPH vs. BMY - Dividend Comparison
AUPH has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 5.20%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
AUPH Aurinia Pharmaceuticals Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
BMY Bristol-Myers Squibb Company | 5.20% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% | 2.46% |
Drawdowns
AUPH vs. BMY - Drawdown Comparison
The maximum AUPH drawdown since its inception was -87.58%, which is greater than BMY's maximum drawdown of -70.62%. Use the drawdown chart below to compare losses from any high point for AUPH and BMY. For additional features, visit the drawdowns tool.
Volatility
AUPH vs. BMY - Volatility Comparison
The current volatility for Aurinia Pharmaceuticals Inc. (AUPH) is 9.62%, while Bristol-Myers Squibb Company (BMY) has a volatility of 10.24%. This indicates that AUPH experiences smaller price fluctuations and is considered to be less risky than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
AUPH vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Aurinia Pharmaceuticals Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
AUPH vs. BMY - Profitability Comparison
AUPH - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Aurinia Pharmaceuticals Inc. reported a gross profit of 54.32M and revenue of 59.87M. Therefore, the gross margin over that period was 90.7%.
BMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Bristol-Myers Squibb Company reported a gross profit of 8.17B and revenue of 11.20B. Therefore, the gross margin over that period was 72.9%.
AUPH - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Aurinia Pharmaceuticals Inc. reported an operating income of -1.67M and revenue of 59.87M, resulting in an operating margin of -2.8%.
BMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Bristol-Myers Squibb Company reported an operating income of 3.52B and revenue of 11.20B, resulting in an operating margin of 31.4%.
AUPH - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Aurinia Pharmaceuticals Inc. reported a net income of 1.43M and revenue of 59.87M, resulting in a net margin of 2.4%.
BMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Bristol-Myers Squibb Company reported a net income of 2.46B and revenue of 11.20B, resulting in a net margin of 21.9%.